Insights

Strategic partnerships Inflammatix has recently partnered with University of Nebraska Medical Center to support rapid hantavirus outbreak response using TriVerity, indicating openness to collaborations with academic medical centers and potential for co-development or joint deployment opportunities in emergency and critical care settings.

Series E traction A $57 million Series E financing round in 2024, led by prominent venture firms, signals strong investor confidence and a scalable commercialization plan, suggesting readiness to expand sales outreach to larger health systems and multi-site deployments.

Clinical leadership Appointment of a chief medical officer with extensive experience in acute care and monitoring at Medtronic highlights a focus on clinical credibility and payer- and hospital-facing value storytelling, aiding conversations with hospital C-suite and risk/quality leaders.

Value-based care fit TriVerity’s rapid three-way infection and deterioration assessment aligns with antimicrobial stewardship and operational efficiency aims, presenting a compelling case to health systems pursuing value-based care, reduced ICU transfers, and shorter ED stays.

Global health expansion Active collaboration for rapid outbreak response and a scalable AI-driven immune profiling platform position Inflammatix to target large health networks, academic centers, and government or public health partnerships for disease surveillance and critical care decision support.

Similar companies to Inflammatix, Inc.

Inflammatix, Inc. Tech Stack

Inflammatix, Inc. uses 8 technology products and services including HubSpot Analytics, SAS, OneTrust, and more. Explore Inflammatix, Inc.'s tech stack below.

Media & News

Inflammatix, Inc.'s Email Address Formats

Inflammatix, Inc. uses at least 4 email formats:
Inflammatix, Inc. Email FormatsExamplePercentage
FLast@inflammatix.comJDoe@inflammatix.com
87%
First@inflammatix.comJohn@inflammatix.com
6%
Last@inflammatix.comDoe@inflammatix.com
5%
First.Last@inflammatix.comJohn.Doe@inflammatix.com
2%

Frequently Asked Questions

What is Inflammatix, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Inflammatix, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Inflammatix, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Inflammatix, Inc.'s official website is inflammatix.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Inflammatix, Inc. generate?

Minus sign iconPlus sign icon
As of October 2026, Inflammatix, Inc.'s annual revenue is estimated to be $25M - $50M.

What is Inflammatix, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Inflammatix, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Inflammatix, Inc. have currently?

Minus sign iconPlus sign icon
As of October 2026, Inflammatix, Inc. has approximately 74 employees across 2 continents, including North America and Europe. Key team members include Senior Director (head Of) Clinical Operations & Da: A. M., Vice President, Marketing: N. M. and Director, Instrument Manufacturing: P. A. Explore Inflammatix, Inc.'s employee directory with LeadIQ.

What industry does Inflammatix, Inc. belong to?

Minus sign iconPlus sign icon
Inflammatix, Inc. operates in the Biotechnology Research industry.

What technology does Inflammatix, Inc. use?

Minus sign iconPlus sign icon
Inflammatix, Inc.'s tech stack includes HubSpot Analytics, SAS, OneTrust, Microsoft Dynamics, Atlassian Jira, WP Engine, Smartsheet and BambooHR.

What is Inflammatix, Inc.'s email format?

Minus sign iconPlus sign icon
Inflammatix, Inc.'s email format typically follows the pattern of FLast@inflammatix.com. Find more Inflammatix, Inc. email formats with LeadIQ.

How much funding has Inflammatix, Inc. raised to date?

Minus sign iconPlus sign icon
As of October 2026, Inflammatix, Inc. has raised $195M in funding. The last funding round occurred on Sep 12, 2024 for $57M.

When was Inflammatix, Inc. founded?

Minus sign iconPlus sign icon
Inflammatix, Inc. was founded in 2016.
Inflammatix, Inc. logo

Inflammatix, Inc.

Biotechnology ResearchCalifornia, United States51-200 Employees

Inflammatix is a biotechnology research company based in Sunnyvale, California, focused on emergency and critical care medicine by analyzing the body’s immune response to inform decisions for patients with suspected acute infection or sepsis. Its FDA-cleared TriVerity test is a rapid blood assay that uses AI analysis of immune mRNA expression to deliver three results in about 30 minutes: the likelihood of bacterial infection, the likelihood of viral infection, and the risk of near-term clinical deterioration. This approach supports risk stratification and clinical assessment in the emergency department, helping clinicians determine which patients may require closer monitoring or inpatient care versus lower-acuity pathways. The insights generated from immune response data are intended to support real-time clinical decision-making while aligning with health-system priorities such as operational efficiency and antimicrobial stewardship.

The company serves clinicians and health systems facing acute infectious presentations in emergency settings, seeking to reduce diagnostic uncertainty at the point of care. It operates within the biotechnology diagnostics space, positioned at the intersection of molecular diagnostics and critical-care decision support. Inflammatix recently partnered with the University of Nebraska Medical Center to support rapid hantavirus outbreak response using TriVerity, illustrating a current application of its platform to public health emergencies.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
51-200

Section iconFunding & Financials

  • $195M

    Inflammatix, Inc. has raised a total of $195M of funding over 9 rounds. Their latest funding round was raised on Sep 12, 2024 in the amount of $57M as a Series E.

  • $25M - $50M

    Inflammatix, Inc.'s revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.